Can You Take Mounjaro If You Have Osteoporosis? - Guide | Cured Pharmacy

Can You Take Mounjaro If You Have Osteoporosis?

Mounjaro Weight Loss Injections (Tirzepatide) KwikPen

Featured Product

Mounjaro Weight Loss Injections (Tirzepatide) KwikPen

From £145.00£124.99UK-based prescribers · Discreet delivery · Free private prescription
Start Assessment →✓ Lowest price guarantee
DISCOUNT CODE: FIRST20

£20 off for new patients

Tarun Kumar, Prescribing Pharmacist at Cured Pharmacy

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Reviewed on: 16 June 2026

Last Updated: 13 August 2026

If you have been diagnosed with osteoporosis and are struggling with your weight, you may be wondering whether Mounjaro is a safe and suitable option for you. It is a genuinely important question, because while Mounjaro has transformed weight management for millions of people across the UK, its relationship with bone density and fracture risk is something every patient and clinician needs to think about carefully. This guide walks you through the science, the risks, the safeguards, and the practical steps you can take to protect your bones while still working towards a healthier weight.

Quick Summary

Mounjaro (tirzepatide) is a powerful GLP-1 and GIP receptor agonist licensed in the UK for weight management and type 2 diabetes. For people with osteoporosis, the decision to use it is nuanced — the benefits of weight loss must be carefully balanced against the well-documented risk of bone loss that can accompany rapid reductions in body weight.

  • Mounjaro is not automatically contraindicated in osteoporosis, but it does require careful clinical assessment before use.
  • Rapid weight loss — common with Mounjaro — can reduce bone mineral density, particularly in older adults.
  • Muscle loss (lean mass reduction) during weight loss may further increase fracture risk in people with osteoporosis.
  • Protective strategies such as calcium and vitamin D supplementation, resistance exercise, and bisphosphonate therapy can reduce bone-related risks.
  • A prescriber experienced in both metabolic health and bone health should oversee your treatment plan.

Bone Health Risk Checker for Mounjaro Users

Answer these quick questions to understand your personal bone health considerations before starting Mounjaro.

Table of Contents

  1. What Is Mounjaro and How Does It Work?
  2. Understanding Osteoporosis and Bone Fragility
  3. Can You Take Mounjaro If You Have Osteoporosis? The Clinical Picture
  4. How Rapid Weight Loss Affects Bone Density
  5. How to Protect Your Bones While Taking Mounjaro
  6. Mounjaro and Bone-Protecting Medications: What You Need to Know
  7. Key Takeaways
  8. When to Seek Professional Advice
  9. Scientific References
  10. Frequently Asked Questions

What Is Mounjaro and How Does It Work?

Mounjaro is the brand name for tirzepatide, a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. It was first approved in the UK for type 2 diabetes management and subsequently gained approval for chronic weight management in adults with obesity or overweight and at least one weight-related health condition. Unlike older GLP-1 medications such as semaglutide, Mounjaro targets two incretin hormone pathways simultaneously, which is why clinical trials have shown it to produce some of the most significant weight loss results of any licensed medication to date.

The medication works primarily by slowing gastric emptying, reducing appetite, and improving insulin sensitivity. Patients typically start on 2.5 mg per week, with the dose gradually increased over several months to a maximum of 15 mg weekly. In trials, patients lost on average between 15% and 22% of their total body weight — a level of reduction that, while deeply beneficial for metabolic health, brings its own physiological consequences that need careful management. If you are exploring weight loss treatment options, understanding those consequences is essential before you begin.

Understanding Osteoporosis and Bone Fragility

Osteoporosis is a condition characterised by reduced bone mineral density and deterioration of bone microarchitecture, leading to bones that are more porous and significantly more susceptible to fracture. In the UK, it is estimated that around 3.5 million people live with osteoporosis, with postmenopausal women and older adults being the most commonly affected groups. However, men and younger adults can also develop the condition, particularly following long-term corticosteroid use, malabsorption disorders, or hormonal imbalances.

Bone is a living tissue that undergoes constant remodelling — old bone is broken down by cells called osteoclasts and replaced by new bone laid down by osteoblasts. In osteoporosis, this balance tips towards more breakdown than formation, resulting in progressive bone loss over time. A DEXA scan (dual-energy X-ray absorptiometry) is used to measure bone mineral density (BMD) and assign a T-score; a T-score of minus 2.5 or lower confirms osteoporosis. The most common fracture sites are the hip, spine, and wrist, and a fragility fracture — one caused by a fall from standing height or less — is often the first sign that osteoporosis is present.

  • Osteoporosis affects approximately 1 in 2 women and 1 in 5 men over 50 in the UK during their lifetime.
  • Fractures related to osteoporosis cost the NHS an estimated £4.4 billion annually.
  • Many people do not know they have osteoporosis until a fracture occurs.
  • Risk factors include smoking, low body weight, physical inactivity, low calcium intake, and certain medications.

Can You Take Mounjaro If You Have Osteoporosis? The Clinical Picture

Can you take Mounjaro if you have osteoporosis? The honest clinical answer is: it depends, and it requires careful, individualised assessment. Mounjaro does not appear on the list of absolute contraindications set out by the Medicines and Healthcare products Regulatory Agency (MHRA), meaning it is not automatically ruled out for people with osteoporosis. However, this does not mean it is without significant bone-related risk in this population. The concern lies not with the medication itself acting directly on bone — though some emerging data is beginning to explore GIP receptor activity on osteoblasts — but rather with the metabolic consequences of the substantial weight loss that Mounjaro produces.

In 2026, clinicians and researchers across the UK are increasingly focused on what is sometimes called the "obesity paradox" in bone health: while excess body weight is associated with numerous serious health conditions, it is also protective of bone density. Adipose (fat) tissue produces oestrogen and mechanically loads the skeleton, both of which stimulate bone formation. When that protective weight is lost rapidly — as frequently occurs with Mounjaro — bone mineral density can decline in tandem. Data from the SURMOUNT clinical trials showed that tirzepatide users experienced modest but measurable reductions in bone mineral density at the hip and lumbar spine, consistent with findings seen in other GLP-1 class medications.

For someone who already has compromised bone density due to osteoporosis, even a modest additional reduction in BMD could push them into a significantly higher fracture risk category. This is the core clinical concern that any prescriber should be weighing carefully when a patient with osteoporosis requests Mounjaro for weight management.

  • Mounjaro is not contraindicated in osteoporosis, but the risk-benefit balance must be assessed individually.
  • The SURMOUNT trials noted reductions in bone mineral density at the hip and spine in tirzepatide users.
  • The degree of bone loss risk tends to correlate with the amount and speed of weight lost.
  • Older adults and postmenopausal women with osteoporosis face the highest compound risk.
  • A baseline DEXA scan before starting Mounjaro is strongly advisable in at-risk patients.

How Rapid Weight Loss Affects Bone Density

The relationship between weight loss and bone health is one that many patients are surprised to learn about. Most people understand intuitively that being overweight is harmful to the heart, joints, and metabolic health. Far fewer appreciate that body weight — including fat mass — plays an active and important role in maintaining bone mineral density. When weight is lost at a slower pace through lifestyle changes alone, the body has time to adapt; bone turnover markers shift, but the impact on overall bone mineral density tends to be relatively minor. The problem with medications like Mounjaro is the speed and magnitude of the weight loss they produce.

When large amounts of body weight are lost quickly, several processes converge to reduce bone density. First, the mechanical load on the skeleton decreases, reducing the stimulus that normally drives new bone formation. Second, fat loss reduces the peripheral production of oestrogen, a hormone critical for bone maintenance in both men and women. Third, if caloric intake drops significantly, patients may not be consuming adequate calcium, vitamin D, or protein — all essential nutrients for skeletal health. Fourth, and perhaps most significantly in the context of GLP-1 medications, there is often a concurrent loss of lean muscle mass alongside fat mass, a process sometimes called sarcopenia.

Muscle and bone health are intimately connected. Muscles pull on bones during contraction, stimulating osteoblast activity and new bone formation. When muscle mass falls — as it often does during rapid weight loss — bone loses a key stimulus for remodelling. Research published in journals relevant to UK clinical practice has confirmed that GLP-1 receptor agonists can contribute to lean mass loss if resistance exercise is not incorporated into the weight loss plan, which is why NICE guidance on obesity management consistently recommends combining pharmacotherapy with structured physical activity.

Risk Factor How It Relates to Mounjaro Use Protective Strategy
Reduced mechanical load on bones Less body weight means less stimulus for bone formation Weight-bearing and resistance exercise throughout treatment
Decreased oestrogen from fat tissue Fat loss reduces peripheral oestrogen production Discuss HRT or bisphosphonate therapy with your GP
Inadequate calcium and vitamin D intake Reduced appetite may lower nutrient consumption Daily calcium (1000–1200 mg) and vitamin D (800–1000 IU) supplementation
Lean muscle mass loss (sarcopenia) Muscle loss reduces mechanical stimulation of bone High-protein diet (1.2–1.6 g/kg body weight/day) plus resistance training
Pre-existing low bone mineral density Any further BMD reduction increases fracture risk significantly Baseline and follow-up DEXA scans; consider bone-protecting medication
Delayed gastric emptying affecting medication absorption Mounjaro slows gastric emptying, potentially affecting bisphosphonate absorption Discuss timing and administration of bone medications with prescriber

How to Protect Your Bones While Taking Mounjaro

If you and your prescriber decide that Mounjaro is appropriate for you despite your osteoporosis diagnosis, there are well-evidenced steps you can take to minimise the impact on your bones. None of these guarantees complete protection, but collectively they form a solid clinical strategy that many bone health specialists and pharmacists across the UK now recommend as standard practice for GLP-1 users at elevated bone risk. The most important thing is that these strategies need to be in place from the very start of treatment, not added retrospectively when bone loss has already occurred.

Calcium and vitamin D supplementation should be considered essential for anyone with osteoporosis taking a weight loss medication. The National Osteoporosis Society guidelines recommend a daily intake of 1000–1200 mg of calcium through a combination of diet and supplementation, alongside 800–1000 IU of vitamin D. Because Mounjaro reduces appetite significantly, getting adequate calcium through diet alone becomes much more challenging, making supplementation even more critical. Your pharmacist can help you choose a supplement that will not interact with any other medications you are taking.

Resistance exercise is arguably the single most powerful bone-protective intervention available to people on Mounjaro. Unlike aerobic exercise, which is excellent for cardiovascular health, resistance training — lifting weights, using resistance bands, bodyweight exercises like squats and lunges — directly stimulates bone-forming cells. Clinical guidance updated in 2026 reinforces that structured resistance training at least twice weekly should be a non-negotiable component of any weight loss programme, particularly in people with bone conditions. This also helps to preserve lean muscle mass, addressing the sarcopenia risk associated with rapid weight loss.

  • Take calcium and vitamin D supplements daily throughout Mounjaro treatment.
  • Incorporate resistance exercise at least twice weekly from day one of treatment.
  • Consume adequate protein — aim for 1.2–1.6 g per kilogram of body weight per day.
  • Arrange a baseline DEXA scan before starting, and schedule a follow-up scan after 12 months.
  • Keep your GP informed about your Mounjaro treatment so they can coordinate your osteoporosis care.
  • Discuss whether bisphosphonate therapy should be started or continued alongside Mounjaro.

Mounjaro and Bone-Protecting Medications: What You Need to Know

Many people with osteoporosis are already taking medications such as alendronic acid (a bisphosphonate), risedronate, denosumab, or strontium ranelate to protect their bone mineral density. If you are in this group and considering adding Mounjaro to your treatment plan, there are important pharmacological interactions and practical considerations to be aware of. The most clinically relevant concern relates to bisphosphonates and the way Mounjaro affects gastric emptying.

Bisphosphonates like alendronic acid are notoriously sensitive to the conditions under which they are taken. They must be swallowed with a full glass of water, in an upright position, on an empty stomach, at least 30 minutes before any food or other medication. Their oral bioavailability is already very low — typically less than 1% of the dose is absorbed — and anything that alters the gastric environment can further reduce this. Because Mounjaro slows gastric emptying quite significantly, there is a plausible concern that the absorption of orally administered bisphosphonates could be affected, though dedicated studies on this specific interaction remain limited in 2026. This is something your prescriber must carefully consider.

Denosumab (brand name Prolia), which is given as a subcutaneous injection every six months, does not carry the same absorption concerns as oral bisphosphonates and is generally easier to co-manage alongside Mounjaro. However, the overall bone mineral density trajectory must still be monitored, because the combined effect of denosumab and the bone loss associated with rapid weight reduction is not yet fully characterised in long-term studies. Your prescriber should be reviewing your complete medication list before initiating any new treatment.

  • Always inform your prescriber of all bone-protecting medications before starting Mounjaro.
  • Mounjaro's gastric-emptying effects may theoretically reduce the absorption of oral bisphosphonates.
  • Injectable bone treatments like denosumab do not carry the same absorption risk as oral options.
  • Regular blood tests to check calcium, vitamin D, and bone turnover markers are advisable.
  • Your GP or rheumatologist should review your osteoporosis management plan when Mounjaro is introduced.

Key Takeaways

  • Mounjaro is not automatically contraindicated in osteoporosis, but requires a thorough individual risk-benefit assessment before prescribing.
  • Rapid, significant weight loss caused by Mounjaro can reduce bone mineral density, which is particularly concerning for those who already have osteoporosis.
  • Protective strategies — including calcium and vitamin D supplementation, resistance exercise, and adequate protein intake — are essential from the start of treatment.
  • Interactions between Mounjaro and oral bisphosphonates are a clinical concern that must be discussed with your prescriber.
  • Regular monitoring with DEXA scans and blood tests allows early detection and management of any bone density changes during treatment.

When to Seek Professional Advice

You should speak with your GP, prescribing pharmacist, or a specialist as soon as possible in any of the following situations. Do not delay seeking advice if you are concerned about your bone health while taking or considering Mounjaro.

  • You have been diagnosed with osteoporosis or osteopenia and want to start Mounjaro — seek assessment before beginning treatment.
  • You are already taking Mounjaro and have been recently diagnosed with osteoporosis during treatment.
  • You experience a fracture or fall while taking Mounjaro, even if it seems minor.
  • You are on bisphosphonates or other bone medications and are unsure how to manage them alongside Mounjaro.
  • You notice significant muscle weakness or unexplained back or joint pain during your Mounjaro treatment.
  • You are an older adult, postmenopausal woman, or have other significant risk factors for fracture and are considering GLP-1 therapy for the first time.

Our team at Cured Pharmacy includes UK-registered prescribing pharmacists who can provide a full clinical assessment and help you explore your options safely. All consultations are carried out in line with current NICE guidance and MHRA regulations to ensure you receive care that is both evidence-based and personalised to your situation.

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today.

Once you complete a short online assessment, you will be able to choose your preferred treatment and quantity from a list of safe, medically approved options tailored to you.

Start My AssessmentReturning Customer?Log In to Your Account

Frequently Asked Questions

How long does it take Mounjaro to affect bone density?

How long Mounjaro takes to affect bone density is not fully established, but studies suggest bone loss linked to rapid weight reduction can begin within the first few months of treatment. Ongoing monitoring of bone health is recommended throughout your treatment, particularly if you already have a diagnosis of osteoporosis or osteopenia.

Is it safe to take Mounjaro with bisphosphonates like alendronic acid?

Taking Mounjaro with bisphosphonates like alendronic acid is generally considered to be clinically manageable, but it requires careful medical supervision. Mounjaro can delay gastric emptying, which may affect how bisphosphonates are absorbed. Your prescriber should review your full medication list before starting Mounjaro alongside any bone-protecting treatment.

Can you take Mounjaro if you have osteoporosis and type 2 diabetes?

You can potentially take Mounjaro if you have osteoporosis and type 2 diabetes, but this combination requires a thorough clinical assessment. Mounjaro is licensed for type 2 diabetes management in the UK, and your prescriber will need to weigh the benefits of blood sugar control against the potential risks to your bone health before proceeding.

What is the dose of Mounjaro for someone with bone health concerns?

The dose of Mounjaro for someone with bone health concerns follows the standard UK titration schedule, starting at 2.5 mg weekly for four weeks. However, your prescriber may choose to titrate more slowly or monitor your bone density more frequently if you have osteoporosis, to manage the potential impact of rapid weight loss on bone health.

Scientific References

  1. National Institute for Health and Care Excellence (NICE). Tirzepatide for managing overweight and obesity. Technology Appraisal Guidance TA1026. NICE, 2024. [Accessed 13 August 2026]
  2. Royal Osteoporosis Society (ROS). Clinical Guidance for the Effective Assessment and Management of Osteoporosis. ROS, 2024. [Accessed 13 August 2026]
  3. Medicines and Healthcare products Regulatory Agency (MHRA). Mounjaro (tirzepatide) Product Information and UK Summary of Product Characteristics. MHRA, 2024. [Accessed 13 August 2026]
  4. NICE Guideline NG187: Osteoporosis – assessing the risk of fragility fracture, NICE, 2012 (updated 2017) [Accessed 13 August 2026]
  5. Mounjaro (tirzepatide) Summary of Product Characteristics, Eli Lilly, Electronic Medicines Compendium (EMC), 2023 [Accessed 13 August 2026]
  6. National Osteoporosis Guideline Group (NOGG): Clinical guideline for the prevention and treatment of osteoporosis, NOGG, 2021 [Accessed 13 August 2026]
  7. Lundgren JR et al., "Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised controlled trial," Diabetes, Obesity and Metabolism, 2021 [Accessed 13 August 2026]
  8. NICE Technology Appraisal TA875: Tirzepatide for managing overweight and obesity in adults, NICE, 2023 [Accessed 13 August 2026]
  9. Royal Osteoporosis Society: Strong, Steady and Straight – an expert consensus statement on physical activity and exercise for osteoporosis, ROS, 2019 [Accessed 13 August 2026]
  10. NICE Guideline NG187: Osteoporosis - assessing the risk of fragility fracture, NICE, 2012 (updated 2017) [Accessed 13 August 2026]
  11. Mounjaro (tirzepatide) 2.5mg solution for injection - Summary of Product Characteristics, Electronic Medicines Compendium (EMC), Eli Lilly, 2023 [Accessed 13 August 2026]
  12. Compan V et al., "GLP-1 receptor agonists and bone metabolism: a review of preclinical and clinical evidence", Journal of Endocrinological Investigation, 2023 [Accessed 13 August 2026]
  13. NICE Technology Appraisal TA943: Tirzepatide for managing overweight and obesity, NICE, 2024 [Accessed 13 August 2026]
  14. Weight and Osteoporosis - risk factors overview, National Osteoporosis Society (Royal Osteoporosis Society), 2023 [Accessed 13 August 2026]
  15. Bilezikian JP et al., "Bone loss following intentional weight loss: mechanisms and clinical implications", The Lancet Diabetes & Endocrinology, 2023 [Accessed 13 August 2026]
Back to blog